Exosomes in Aesthetics: What the Evidence Says
Exosomes are a real object of laboratory research: small vesicles that cells release and that carry material between cells. Products sold for injection under that name are a different matter. They are not a defined or standardised product class, the material in the vial is usually not characterised, no regulator has approved any of them for cosmetic injection, and the results used to sell them come from work in cells, in animals or from uncontrolled case series. Most are also applied immediately after a needling or laser procedure, so even a visible change cannot be attributed to the injected material. This site separates the three questions that get blended together: what is in the vial, what the law currently permits, and what the research can actually establish.
Chongqing West District Hospital, a tertiary general hospital in Jiulongpo District, Chongqing. This is a review of published evidence and regulation, not medical advice, and it is not a recommendation for or against any treatment.
How claims are separated here
Every claim in this review is placed in one of three groups, and the group matters more than the wording. Supported means the claim follows from evidence that can be checked: a regulator has issued a warning, a laboratory has characterised a material and reported a result, an infection has been documented and traced. That regulators have warned about these products, and that birth-tissue material carries an infection risk when injected, are in this group. Plausible but unproven means there is a mechanism, a laboratory finding or a body of clinical enthusiasm, but not the kind of study that establishes what happens in people. Most of the biological story about vesicles sits here, and it is an honest description of the research rather than a dismissal of it. Not supported means the claim is made confidently and nothing carries it.
The reason for grading rather than simply reporting is that the three groups are routinely presented as one. A description of what a vesicle does in a culture dish and a promise about a face are written in the same confident register, and only the first is a finding. Two further distinctions do most of the work on this subject. The first is that a name is not a measurement: calling a preparation an exosome product states nothing about what it contains or how anyone checked. The second is that the biology being real does not make a marketed product real, because the material studied in a laboratory is not the material in a vial sold through a clinic.
Where these products stand with regulators
No exosome product has been approved for cosmetic injection in any market this review can identify, and regulators in several countries have published safety communications saying so. Those communications make four points in common: that no such product is approved for injection, that marketing one for injection is not permitted, that serious adverse events including infections have been reported in people who received such injections, and that a product which has been through an approval process should be used instead.
The status of a product is a separate question from whether it works, and on this subject the two are constantly confused. An approval is a set of obligations rather than a compliment: it means someone specified what the product is, how it is made, what it is for, what dose is given, and what happens when something goes wrong. The absence of approval does not establish that a product is harmful. It establishes that none of those questions has been answered by anyone with the authority and the evidence to answer them.
Regulatory position also varies by jurisdiction, and the variation is routinely misread. Some regulators have made explicit statements. Some have taken action against particular sellers. Others have said little, which reflects the limits of a remit or of resources rather than a judgement that the products are acceptable. In most markets there is no approval for an exosome injectable to hold, so a product cannot carry an approved status from one country into another. The practical consequence is easy to get wrong and worth stating plainly: absence of enforcement is not approval, and a clinic operating openly is not a clinic operating with permission in any positive sense.
What the evidence does establish
These statements can be checked. Each is stated with its own limit rather than as a general reassurance or a general warning.
Exosomes exist and are studied
Supported as a matter of laboratory science. Cells release small membrane-bound vesicles that carry proteins, lipids and nucleic acids, and these are a genuine subject of research with a large published literature. What does not follow from that literature is anything about a product sold for injection, because the material studied and the material sold are not the same thing.
Regulators have issued warnings
Supported and documented. Regulators in several countries have published safety communications stating that no exosome product is approved for injection and that adverse events, including serious infections, have been reported after such injections. The existence of those communications is a fact that can be read directly rather than inferred.
Birth-tissue material carries an infection risk when injected
Supported. Tissue of human origin can carry organisms, and placing it inside tissue rather than on a surface removes the barrier that skin provides. Infections have been documented after injections of unapproved products of this kind, and the regulatory communications say so. The material is not the problem by itself; the injection route is what changes the risk.
The marketed product is usually not characterised
Supported by independent testing, which has found that products labelled as exosomes frequently contain little or no measurable exosome content and vary between batches. The point is not that every product is empty. It is that nothing on the label tells a buyer which case they are in, and the measurement that would settle it is not usually performed.
An effect cannot be attributed to the injected material alone
Supported by the way these products are used. They are typically applied straight after a procedure that deliberately injures the skin, such as microneedling or a fractional laser, and that procedure produces changes of its own. Where the two are done together, no uncontrolled series can say which produced the result.
Claims the evidence does not carry
These claims are common in clinics and in advertising, and none of them is supported. Naming them is the most useful thing this review does.
That the products are a defined or standardised class
Not supported. There is no agreed definition of what an exosome product is, no standard for what it must contain, and no release specification that a batch is measured against. Two vials bearing the same description need not contain the same material, which makes the description a category of marketing rather than of product.
That the vial contains measurable exosomes
Not supported as a general claim. Independent testing has repeatedly found that the measurable content is low, absent or inconsistent with the label. A product may contain material of the right origin and still contain very little of the structure the name refers to, and no buyer can tell without an assay they are not given.
That injections improve skin quality and scars
Not supported. No controlled trial in people establishes this for a marketed product, and no regulator has approved that indication. The accounts that circulate come from uncontrolled case series, where improvement over time, the co-administered needling or laser, and the expectations of a paying patient are all present and none is separated out.
That these products are approved for cosmetic injection
Not supported, and contradicted by the regulators who have published on the subject. Approval is specific to an indication, a population and a jurisdiction, and no approval of this kind exists. A product made as a cosmetic ingredient, shipped as a laboratory reagent and injected in a clinic has not been assessed for the way it is actually used.
That a serum applied to the skin does much at all
Limited at best. A product sold as a cosmetic serum is regulated as a cosmetic, which means it may not claim to treat a condition or to change the structure of the body. Whatever it does for the surface of the skin, the claims made for an injected product cannot be transferred to it, and the two are often sold side by side as though one supported the other.
What the risks are, stated plainly
The first risk is not a biological one. It is the risk of treating a sales sentence as a finding: of accepting a product on the strength of a phrase that sounds like evidence, and of agreeing to an injection whose contents, dose and manufacturing standard nobody has established. That is the risk this site exists to reduce, and it is the one a reader can act on before anything else.
The documented risks are the ones regulators have reported. Infection is the clearest: tissue-derived material placed inside the skin can carry organisms, infections have followed such injections, and some have been serious enough to need hospital treatment. Because the product is usually not recorded by name, batch and source, an infection cannot reliably be traced back to the material that caused it, and other people who received the same batch cannot be identified. There is also the ordinary risk of any injection: bleeding, bruising, pain, and a reaction at the site, with no labelled product or manufacturer to report it to.
The risks that are unknown belong on the same list, because their absence from it is what makes the marketing possible. No defined dose means no one can say what a safe amount would be. No controlled trials mean no one can describe the effects that appear months or years later. No systematic collection of adverse events means harm that occurs is reported only by whoever chooses to report it, which makes the true rate of any complication unmeasurable. And the manufacturing process is unstandardised, so a reaction to one batch says little about the next. There is a further limit on the evidence itself: most published work uses material produced and characterised for research, at a stated content and with confirming assays. That material is not the material in a commercial vial, so the laboratory record and the clinical claim describe two different things.
What else is on the table, including doing nothing
Doing nothing is an option, and for many people it is the right first one. Most skin concerns that lead someone toward an exosome product are not urgent, and taking time over a decision that involves an unapproved injectable costs nothing but patience. Where something is being considered, the useful comparison is not between exosome products, since none of them has established what the others have not, but between an unproven injectable and approaches whose position is documented.
For texture, fine lines and surface quality, the options with the longest record are procedures that act on the skin directly: microneedling, fractional laser resurfacing, chemical peeling, and the energy-based devices. Each of those produces its change by injuring the skin in a controlled way and letting the repair response follow, and each has been studied in people with defined outcomes. They carry real downtime and real risks, including pigment change and, rarely, scarring, and they are not interchangeable with one another. What they have that an exosome injection does not is a body of clinical evidence, a defined procedure, and a regulatory position.
For volume loss or a fold that has deepened, the alternative is a filler or a biostimulator, both of which have approved products, defined materials and known complication profiles including the fact that some can be dissolved and some cannot. For pigment, redness or a barrier problem, the answer is usually a medical skin assessment first. Where skin has genuinely laxity rather than a surface problem, no injectable addresses it and the honest options are an energy-based tightening procedure or an operation. And for anyone whose main concern is that a product is new and therefore promising, the reasonable position is to wait: if the characterisation work described elsewhere on this site is done, the answer becomes checkable, and until then being early carries the risk without the evidence.
How this review is kept current
This subject moves on two different clocks. The science moves slowly, because characterising a material and running controlled trials takes years. Regulation and enforcement move faster, because a regulator can issue a warning or act against a seller on the evidence it already has, and public enthusiasm moves fastest of all, which is why a claim can be everywhere before any evidence for it exists and can remain everywhere after none has appeared.
This review is therefore dated and reviewed on a short cycle, and each review covers three things. The first is whether any claim has moved between the three grading groups in either direction, because a claim can become supported as well as cease to be. The second is regulatory position, since a new safety communication or an enforcement action is a checkable fact that a reader is entitled to have current. The third is whether the evidence base has changed in kind rather than in quantity: an additional case series is a different event from the first controlled trial, and only the second can settle a question the first can only describe.
Where this review is wrong, the correction is made to the page itself rather than noted elsewhere, and the date of the most recent review is shown on every page. Where a question is genuinely unresolved, this review says that it is unresolved rather than resolving it by tone, which is a deliberate editorial position: a reader who is told that the answer is not yet known can weigh the uncertainty, and a reader who is handed confidence in either direction cannot. Nothing here is offered as a service, and no page on this site offers an assessment or an appointment.
Exosome claims, evidence and approval status
Every row is a claim you are likely to meet, placed against what the evidence behind it actually is and what regulators have done about it. The two right-hand columns answer two different questions, which is why they are kept apart.
The evidence guides
Each guide answers one question about the claim rather than about a treatment. Read the two or three that match what you are trying to establish.
What a Product Labelled Exosome Actually Contains
What a vial sold as an exosome actually contains, what a laboratory would have to measure to say, and the three facts a label rarely provides.
Read the guide →Why Exosomes Are Not an Approved Product Class
Why an injected exosome product belongs to no regulated category, and what an approval would have established that its absence leaves unestablished.
Read the guide →What Regulators Have Said About Exosome Injections
What regulators have published about unapproved exosome and birth tissue injections, what a warning does and does not establish, and why silence is not approval.
Read the guide →Birth Tissue Products and the Infection Risk
Donor sourcing, sterility and the injection route: how an unapproved tissue-derived product causes harm, and why a reported infection cannot be traced to a batch.
Read the guide →The Evidence Exosome Marketing Rests On
What in-vitro work, animal models and case series can each establish, and why a needling or laser procedure done at the same time confounds the result.
Read the guide →How Exosome Claims Are Worded to Avoid Regulation
Exosome-rich, conditioned media, growth factors, cosmeceutical: how each wording keeps a product outside a category that would impose obligations.
Read the guide →A question about the exosome evidence?
This site is an evidence review rather than a booking page, and it does not recommend for or against any product or offer an assessment in relation to anything it describes. If you have a question about this review, or about what the evidence does and does not cover, contact the team and ask.
Frequently asked questions
What is a product sold as an exosome actually made of?
Usually a liquid or a powder derived from cultured cells or from tissue, containing proteins, salts, sugars and particles of many sizes. Where independent laboratories have measured the exosome content, it has often been low, absent or inconsistent between batches. Nothing on a typical label states the source, the method of measurement or the result, so the contents are not verifiable by a buyer.
If exosomes are real in research, why is that not evidence for a product?
Because the material in the research and the material in a vial are different things. Laboratory work uses preparations produced and characterised for the purpose, at a stated content and with confirming assays. A commercial product carries no such characterisation, and the studies were not done on it. The biology being real tells you the subject is worth studying; it tells you nothing about what is in a particular vial.
What have regulators done about exosome injections?
Several have published safety communications stating that no such product is approved for injection, that marketing one for that use is not permitted, and that serious adverse events including infections have been reported after such injections. Some have acted against particular sellers. Others have said little, which reflects the limits of a remit rather than a judgement that the products are acceptable.
Why is an exosome product usually combined with microneedling or laser?
Because the needling or laser produces a change on its own, and anything applied at the same time is then credited with it. In an uncontrolled series the two cannot be separated, so the combination makes a result harder to attribute rather than easier. It also gives a clinic a way to offer something new alongside a procedure that already has an evidence base.
Could a clinic call it research and still charge for it?
It could, and that is the point of the framing. Legitimate research involving patients needs a protocol approved by an independent ethics committee, a defined intervention, oversight, and a consent process that states what is not known. Where those are absent, the word research is being used to explain the lack of approval rather than to describe a study.
What would have to change for the evidence to support these products?
An identity assay run by someone other than the seller, reported as a number. A standardised manufacturing process with defined release criteria and a validated step that reduces infection risk. A stated dose of a characterised material. And controlled trials in people that separate the injected material from any needling or laser done with it. None of that is unusual; it is the ordinary route.
Part of Regenerative and Emerging Treatments — 9 sites on this topic